Listed

Chemomab Therapeutics Ltd.

CMMBNasdaqCIK 1534248HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Net income−$8.8m, Q1 FY2023
Chemomab Therapeutics Ltd., income statement, quarterly
Line itemUnitQ2 FY20202020-06-30Q3 FY20202020-09-30Q4 FY20202020-12-31Q1 FY20212021-03-31Q2 FY20212021-06-30Q3 FY20212021-09-30Q4 FY20212021-12-31Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31
Research and development$k847Research and development, Q2 FY2020, three months to 2020-06-30$847.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2021-08-13, accession 0001178913-21-002696.Report this figure1,031Research and development, Q3 FY2020, three months to 2020-09-30$1.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure1,254Research and development, Q4 FY2020, three months to 2020-12-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2022-03-30, accession 0001178913-22-001304. Derived: 12-month figure less the 9-month figure.Report this figure1,157Research and development, Q1 FY2021, three months to 2021-03-31$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure1,307Research and development, Q2 FY2021, three months to 2021-06-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure1,487Research and development, Q3 FY2021, three months to 2021-09-30$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure2,383Research and development, Q4 FY2021, three months to 2021-12-31$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 20-F filed 2024-03-28, accession 0001178913-24-001124. Derived: 12-month figure less the 9-month figure.Report this figure2,745Research and development, Q1 FY2022, three months to 2022-03-31$2.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure2,914Research and development, Q2 FY2022, three months to 2022-06-30$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure5,423Research and development, Q3 FY2022, three months to 2022-09-30$5.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure5,895Research and development, Q4 FY2022, three months to 2022-12-31$5.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 20-F filed 2025-04-04, accession 0001178913-25-001205. Derived: 12-month figure less the 9-month figure.Report this figure6,887Research and development, Q1 FY2023, three months to 2023-03-31$6.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure
Income tax$knot reportednot reportednot reportednot reported0.0Income tax, Q2 FY2021, three months to 2021-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure0.0Income tax, Q3 FY2021, three months to 2021-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure0.0Income tax, Q4 FY2021, three months to 2021-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 20-F filed 2024-03-28, accession 0001178913-24-001124. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2022, three months to 2022-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure(544)Income tax, Q2 FY2022, three months to 2022-06-30−$544.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure0.0Income tax, Q3 FY2022, three months to 2022-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure10.0Income tax, Q4 FY2022, three months to 2022-12-31$10.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 20-F filed 2025-04-04, accession 0001178913-25-001205. Derived: 12-month figure less the 9-month figure.Report this figure21.0Income tax, Q1 FY2023, three months to 2023-03-31$21.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure
Net income$k(1,081)Net income, Q2 FY2020, three months to 2020-06-30−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure(1,224)Net income, Q3 FY2020, three months to 2020-09-30−$1.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure(1,951)Net income, Q4 FY2020, three months to 2020-12-31−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2022-03-30, accession 0001178913-22-001304. Derived: 12-month figure less the 9-month figure.Report this figure(1,704)Net income, Q1 FY2021, three months to 2021-03-31−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure(2,770)Net income, Q2 FY2021, three months to 2021-06-30−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure(2,968)Net income, Q3 FY2021, three months to 2021-09-30−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure(5,036)Net income, Q4 FY2021, three months to 2021-12-31−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 20-F filed 2024-03-28, accession 0001178913-24-001124. Derived: 12-month figure less the 9-month figure.Report this figure(5,104)Net income, Q1 FY2022, three months to 2022-03-31−$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure(6,190)Net income, Q2 FY2022, three months to 2022-06-30−$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure(8,080)Net income, Q3 FY2022, three months to 2022-09-30−$8.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure(8,272)Net income, Q4 FY2022, three months to 2022-12-31−$8.3m. XBRL concept us-gaap:NetIncomeLoss. 20-F filed 2025-04-04, accession 0001178913-25-001205. Derived: 12-month figure less the 9-month figure.Report this figure(8,753)Net income, Q1 FY2023, three months to 2023-03-31−$8.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure
Diluted EPS$ per share0.01Diluted EPS, Q2 FY2020, three months to 2020-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-Q filed 2021-08-13, accession 0001178913-21-002696.Report this figure0.01Diluted EPS, Q3 FY2020, three months to 2020-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figurenot reported0.01Diluted EPS, Q1 FY2021, three months to 2021-03-31$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure0.01Diluted EPS, Q2 FY2021, three months to 2021-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure0.01Diluted EPS, Q3 FY2021, three months to 2021-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figurenot reported0.02Diluted EPS, Q1 FY2022, three months to 2022-03-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure0.03Diluted EPS, Q2 FY2022, three months to 2022-06-30$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure0.04Diluted EPS, Q3 FY2022, three months to 2022-09-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figurenot reported0.04Diluted EPS, Q1 FY2023, three months to 2023-03-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure
Basic EPS$ per sharenot reportednot reportednot reportednot reported0.01Basic EPS, Q2 FY2021, three months to 2021-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure0.01Basic EPS, Q3 FY2021, three months to 2021-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figurenot reported0.02Basic EPS, Q1 FY2022, three months to 2022-03-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure0.03Basic EPS, Q2 FY2022, three months to 2022-06-30$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure0.04Basic EPS, Q3 FY2022, three months to 2022-09-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figurenot reported0.04Basic EPS, Q1 FY2023, three months to 2023-03-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure

Balance sheet

Cash and equivalents$7.6m, FY2025
Shareholders' equity$12.3m, FY2025
Chemomab Therapeutics Ltd., balance sheet, quarterly
Line itemUnitQ1 FY20212021-03-31Q2 FY20212021-06-30Q3 FY20212021-09-30FY20212021-12-31Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30FY20222022-12-31Q1 FY20232023-03-31FY20232023-12-31FY20242024-12-31FY20252025-12-31
Cash and equivalents$m58.2Cash and equivalents, Q1 FY2021, at 2021-03-31$58.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2021-05-13, accession 0001104659-21-065588.Report this figure45.4Cash and equivalents, Q2 FY2021, at 2021-06-30$45.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2021-08-13, accession 0001178913-21-002696.Report this figure37.7Cash and equivalents, Q3 FY2021, at 2021-09-30$37.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure15.2Cash and equivalents, FY2021, at 2021-12-31$15.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2023-03-20, accession 0001178913-23-001041.Report this figure13.8Cash and equivalents, Q1 FY2022, at 2022-03-31$13.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure9.9Cash and equivalents, Q2 FY2022, at 2022-06-30$9.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure10.7Cash and equivalents, Q3 FY2022, at 2022-09-30$10.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure13.5Cash and equivalents, FY2022, at 2022-12-31$13.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 20-F filed 2024-03-28, accession 0001178913-24-001124.Report this figure20.8Cash and equivalents, Q1 FY2023, at 2023-03-31$20.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure9.3Cash and equivalents, FY2023, at 2023-12-31$9.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure6.1Cash and equivalents, FY2024, at 2024-12-31$6.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure7.6Cash and equivalents, FY2025, at 2025-12-31$7.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure
Current assets$m59.5Current assets, Q1 FY2021, at 2021-03-31$59.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2021-05-13, accession 0001104659-21-065588.Report this figure68.8Current assets, Q2 FY2021, at 2021-06-30$68.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2021-08-13, accession 0001178913-21-002696.Report this figure65.8Current assets, Q3 FY2021, at 2021-09-30$65.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure62.7Current assets, FY2021, at 2021-12-31$62.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2023-03-20, accession 0001178913-23-001041.Report this figure59.3Current assets, Q1 FY2022, at 2022-03-31$59.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure54.8Current assets, Q2 FY2022, at 2022-06-30$54.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure48.7Current assets, Q3 FY2022, at 2022-09-30$48.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure41.7Current assets, FY2022, at 2022-12-31$41.7m. XBRL concept us-gaap:AssetsCurrent. 20-F filed 2024-03-28, accession 0001178913-24-001124.Report this figure33.8Current assets, Q1 FY2023, at 2023-03-31$33.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure20.9Current assets, FY2023, at 2023-12-31$20.9m. XBRL concept us-gaap:AssetsCurrent. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure16.0Current assets, FY2024, at 2024-12-31$16.0m. XBRL concept us-gaap:AssetsCurrent. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure13.4Current assets, FY2025, at 2025-12-31$13.4m. XBRL concept us-gaap:AssetsCurrent. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure
Total assets$m60.1Total assets, Q1 FY2021, at 2021-03-31$60.1m. XBRL concept us-gaap:Assets. 10-Q filed 2021-05-13, accession 0001104659-21-065588.Report this figure70.5Total assets, Q2 FY2021, at 2021-06-30$70.5m. XBRL concept us-gaap:Assets. 10-Q filed 2021-08-13, accession 0001178913-21-002696.Report this figure67.4Total assets, Q3 FY2021, at 2021-09-30$67.4m. XBRL concept us-gaap:Assets. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure64.4Total assets, FY2021, at 2021-12-31$64.4m. XBRL concept us-gaap:Assets. 10-K filed 2023-03-20, accession 0001178913-23-001041.Report this figure61.0Total assets, Q1 FY2022, at 2022-03-31$61.0m. XBRL concept us-gaap:Assets. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure56.4Total assets, Q2 FY2022, at 2022-06-30$56.4m. XBRL concept us-gaap:Assets. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure50.2Total assets, Q3 FY2022, at 2022-09-30$50.2m. XBRL concept us-gaap:Assets. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure43.1Total assets, FY2022, at 2022-12-31$43.1m. XBRL concept us-gaap:Assets. 20-F filed 2024-03-28, accession 0001178913-24-001124.Report this figure35.0Total assets, Q1 FY2023, at 2023-03-31$35.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure22.2Total assets, FY2023, at 2023-12-31$22.2m. XBRL concept us-gaap:Assets. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure17.0Total assets, FY2024, at 2024-12-31$17.0m. XBRL concept us-gaap:Assets. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure13.8Total assets, FY2025, at 2025-12-31$13.8m. XBRL concept us-gaap:Assets. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure
Current liabilities$m4.6Current liabilities, Q1 FY2021, at 2021-03-31$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2021-05-13, accession 0001104659-21-065588.Report this figure2.2Current liabilities, Q2 FY2021, at 2021-06-30$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2021-08-13, accession 0001178913-21-002696.Report this figure1.6Current liabilities, Q3 FY2021, at 2021-09-30$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure2.7Current liabilities, FY2021, at 2021-12-31$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2023-03-20, accession 0001178913-23-001041.Report this figure3.5Current liabilities, Q1 FY2022, at 2022-03-31$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure4.4Current liabilities, Q2 FY2022, at 2022-06-30$4.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure5.5Current liabilities, Q3 FY2022, at 2022-09-30$5.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure6.7Current liabilities, FY2022, at 2022-12-31$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 20-F filed 2024-03-28, accession 0001178913-24-001124.Report this figure7.0Current liabilities, Q1 FY2023, at 2023-03-31$7.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure4.8Current liabilities, FY2023, at 2023-12-31$4.8m. XBRL concept us-gaap:LiabilitiesCurrent. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure3.2Current liabilities, FY2024, at 2024-12-31$3.2m. XBRL concept us-gaap:LiabilitiesCurrent. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure1.5Current liabilities, FY2025, at 2025-12-31$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure
Total liabilities$m5.0Total liabilities, Q1 FY2021, at 2021-03-31$5.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2021-05-13, accession 0001104659-21-065588.Report this figure2.5Total liabilities, Q2 FY2021, at 2021-06-30$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2021-08-13, accession 0001178913-21-002696.Report this figure1.9Total liabilities, Q3 FY2021, at 2021-09-30$1.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2021-11-12, accession 0001178913-21-003509.Report this figure2.9Total liabilities, FY2021, at 2021-12-31$2.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2023-03-20, accession 0001178913-23-001041.Report this figure3.7Total liabilities, Q1 FY2022, at 2022-03-31$3.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure4.5Total liabilities, Q2 FY2022, at 2022-06-30$4.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure5.6Total liabilities, Q3 FY2022, at 2022-09-30$5.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure6.8Total liabilities, FY2022, at 2022-12-31$6.8m. XBRL concept us-gaap:Liabilities. 20-F filed 2024-03-28, accession 0001178913-24-001124.Report this figure7.1Total liabilities, Q1 FY2023, at 2023-03-31$7.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure5.2Total liabilities, FY2023, at 2023-12-31$5.2m. XBRL concept us-gaap:Liabilities. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure3.4Total liabilities, FY2024, at 2024-12-31$3.4m. XBRL concept us-gaap:Liabilities. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure1.5Total liabilities, FY2025, at 2025-12-31$1.5m. XBRL concept us-gaap:Liabilities. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure
Shareholders' equity$m55.2Shareholders' equity, Q1 FY2021, at 2021-03-31$55.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure68.0Shareholders' equity, Q2 FY2021, at 2021-06-30$68.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure65.5Shareholders' equity, Q3 FY2021, at 2021-09-30$65.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure61.5Shareholders' equity, FY2021, at 2021-12-31$61.5m. XBRL concept us-gaap:StockholdersEquity. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure57.2Shareholders' equity, Q1 FY2022, at 2022-03-31$57.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure51.8Shareholders' equity, Q2 FY2022, at 2022-06-30$51.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure44.6Shareholders' equity, Q3 FY2022, at 2022-09-30$44.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure36.2Shareholders' equity, FY2022, at 2022-12-31$36.2m. XBRL concept us-gaap:StockholdersEquity. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure28.0Shareholders' equity, Q1 FY2023, at 2023-03-31$28.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure17.0Shareholders' equity, FY2023, at 2023-12-31$17.0m. XBRL concept us-gaap:StockholdersEquity. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure13.5Shareholders' equity, FY2024, at 2024-12-31$13.5m. XBRL concept us-gaap:StockholdersEquity. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure12.3Shareholders' equity, FY2025, at 2025-12-31$12.3m. XBRL concept us-gaap:StockholdersEquity. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure

Cash flow

Operating cash flow−$7.2m, Q1 FY2023
Capital expenditure$1.0k, Q1 FY2023
Chemomab Therapeutics Ltd., cash flow, quarterly
Line itemUnitQ2 FY20202020-06-30Q3 FY20202020-09-30Q4 FY20202020-12-31Q1 FY20212021-03-31Q2 FY20212021-06-30Q3 FY20212021-09-30Q4 FY20212021-12-31Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31
Operating cash flow$k(873)Operating cash flow, Q2 FY2020, three months to 2020-06-30−$873.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2021-08-13, accession 0001178913-21-002696. Derived: 6-month figure less the 3-month figure.Report this figure(901)Operating cash flow, Q3 FY2020, three months to 2020-09-30−$901.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2021-11-12, accession 0001178913-21-003509. Derived: 9-month figure less the 6-month figure.Report this figure(1,555)Operating cash flow, Q4 FY2020, three months to 2020-12-31−$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2022-03-30, accession 0001178913-22-001304. Derived: 12-month figure less the 9-month figure.Report this figure(1,293)Operating cash flow, Q1 FY2021, three months to 2021-03-31−$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure(5,607)Operating cash flow, Q2 FY2021, three months to 2021-06-30−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Report this figure(2,580)Operating cash flow, Q3 FY2021, three months to 2021-09-30−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Report this figure(2,894)Operating cash flow, Q4 FY2021, three months to 2021-12-31−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2024-03-28, accession 0001178913-24-001124. Derived: 12-month figure less the 9-month figure.Report this figure(3,711)Operating cash flow, Q1 FY2022, three months to 2022-03-31−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure(5,701)Operating cash flow, Q2 FY2022, three months to 2022-06-30−$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Report this figure(5,255)Operating cash flow, Q3 FY2022, three months to 2022-09-30−$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Report this figure(5,703)Operating cash flow, Q4 FY2022, three months to 2022-12-31−$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2025-04-04, accession 0001178913-25-001205. Derived: 12-month figure less the 9-month figure.Report this figure(7,186)Operating cash flow, Q1 FY2023, three months to 2023-03-31−$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure
Capital expenditure$k7.0Capital expenditure, Q2 FY2020, three months to 2020-06-30$7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2021-08-13, accession 0001178913-21-002696. Derived: 6-month figure less the 3-month figure.Report this figure20.0Capital expenditure, Q3 FY2020, three months to 2020-09-30$20.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2021-11-12, accession 0001178913-21-003509. Derived: 9-month figure less the 6-month figure.Report this figure1.0Capital expenditure, Q4 FY2020, three months to 2020-12-31$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2022-03-30, accession 0001178913-22-001304. Derived: 12-month figure less the 9-month figure.Report this figure3.0Capital expenditure, Q1 FY2021, three months to 2021-03-31$3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-05-12, accession 0001178913-22-001919.Report this figure102Capital expenditure, Q2 FY2021, three months to 2021-06-30$102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2021, three months to 2021-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Report this figure134Capital expenditure, Q4 FY2021, three months to 2021-12-31$134.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2024-03-28, accession 0001178913-24-001124. Derived: 12-month figure less the 9-month figure.Report this figure14.0Capital expenditure, Q1 FY2022, three months to 2022-03-31$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure11.0Capital expenditure, Q2 FY2022, three months to 2022-06-30$11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Report this figure42.0Capital expenditure, Q3 FY2022, three months to 2022-09-30$42.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Report this figure1.0Capital expenditure, Q4 FY2022, three months to 2022-12-31$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2025-04-04, accession 0001178913-25-001205. Derived: 12-month figure less the 9-month figure.Report this figure1.0Capital expenditure, Q1 FY2023, three months to 2023-03-31$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure

Shares

Diluted shares (weighted)221.00m, Q1 FY2023
Chemomab Therapeutics Ltd., shares, quarterly
Line itemUnitQ2 FY20212021-06-30Q3 FY20212021-09-30Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31
Diluted shares (weighted)m shares216Diluted shares (weighted), Q2 FY2021, three months to 2021-06-30216,266,993 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure228Diluted shares (weighted), Q3 FY2021, three months to 2021-09-30227,956,060 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure228Diluted shares (weighted), Q1 FY2022, three months to 2022-03-31228,090,300 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure228Diluted shares (weighted), Q2 FY2022, three months to 2022-06-30228,173,276 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure229Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30228,773,418 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure221Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31220,996,240 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure

Shares outstanding: 575.38mShares outstanding, FY2025, at 2025-12-31575,381,320 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure at Dec 31, 2025, from the cover of the 20-F filed Mar 23, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.